Lebrin, F. et al. Endoglin promotes endothelial cell proliferation and TGF-/ALK1 signal transduction. EMBO J. 23, 4018-4028

Division of Cellular Biochemistry, The Netherlands Cancer Institute, Plesmanlaan, Amsterdam, The Netherlands.
The EMBO Journal (Impact Factor: 10.43). 11/2004; 23(20):4018-28. DOI: 10.1038/sj.emboj.7600386
Source: PubMed


Endoglin is a transmembrane accessory receptor for transforming growth factor-beta (TGF-beta) that is predominantly expressed on proliferating endothelial cells in culture and on angiogenic blood vessels in vivo. Endoglin, as well as other TGF-beta signalling components, is essential during angiogenesis. Mutations in endoglin and activin receptor-like kinase 1 (ALK1), an endothelial specific TGF-beta type I receptor, have been linked to the vascular disorder, hereditary haemorrhagic telangiectasia. However, the function of endoglin in TGF-beta/ALK signalling has remained unclear. Here we report that endoglin is required for efficient TGF-beta/ALK1 signalling, which indirectly inhibits TGF-beta/ALK5 signalling. Endothelial cells lacking endoglin do not grow because TGF-beta/ALK1 signalling is reduced and TGF-beta/ALK5 signalling is increased. Surviving cells adapt to this imbalance by downregulating ALK5 expression in order to proliferate. The ability of endoglin to promote ALK1 signalling also explains why ectopic endoglin expression in endothelial cells promotes proliferation and blocks TGF-beta-induced growth arrest by indirectly reducing TGF-beta/ALK5 signalling. Our results indicate a pivotal role for endoglin in the balance of ALK1 and ALK5 signalling to regulate endothelial cell proliferation.

Download full-text


Available from: Leon Jonker, Feb 26, 2014
57 Reads
  • Source
    • "Shear stress induced expression of eNOS and NO production has been shown to enhance hematopoiesis in ES/EB differentiation assays and also in vivo (Adamo et al., 2009; North et al., 2009). Shear stress has also been shown to increase ENG expression in endothelial cells, which in turn mediates TGF-β/pSmad2 signaling and leads to the increase of eNOS (Lebrin et al., 2004; Seghers et al., 2012). Therefore, we speculated that the increase in definitive hematopoiesis that we observed with ENG induction in FLK1 + and TIE2 + /CD117 + cells could be mediated by the ENG/pSmad2/eNOS/NO endothelial axis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: During embryonic development, hematopoietic cells develop by a process of endothelial-to hematopoietic transition of a specialized population of endothelial cells. These hemogenic endothelium (HE) cells in turn develop from a primitive population of FLK1(+) mesodermal cells. Endoglin (ENG) is an accessory TGF-β receptor that is enriched on the surface of endothelial and hematopoietic stem cells and is also required for the normal development of hemogenic precursors. However, the functional role of ENG during the transition of FLK1(+) mesoderm to hematopoietic cells is ill defined. To address this we used a murine embryonic stem cell model that has been shown to mirror the temporal emergence of these cells in the embryo. We noted that FLK1(+) mesodermal cells expressing ENG generated fewer blast colony-forming cells but had increased hemogenic potential when compared with ENG non-expressing cells. TIE2(+)/CD117(+) HE cells expressing ENG also showed increased hemogenic potential compared with non-expressing cells. To evaluate whether high ENG expression accelerates hematopoiesis, we generated an inducible ENG expressing ES cell line and forced expression in FLK1(+) mesodermal or TIE2(+)/CD117(+) HE cells. High ENG expression at both stages accelerated the emergence of CD45(+) definitive hematopoietic cells. High ENG expression was associated with increased pSMAD2/eNOS expression and NO synthesis in hemogenic precursors. Inhibition of eNOS blunted the ENG induced increase in definitive hematopoiesis. Taken together, these data show that ENG potentiates the emergence of definitive hematopoietic cells by modulating TGF-β/pSMAD2 signalling and increasing eNOS/NO synthesis. © 2015. Published by The Company of Biologists Ltd.
    Biology Open 05/2015; 4(7). DOI:10.1242/bio.011494 · 2.42 Impact Factor
  • Source
    • "As endoglin and ALK1 proteins are predominantly expressed in endothelial cells, these are primary cellular targets of the disease. Thus, HHT manifestations are caused by a disturbance in the TGF-β signaling pathway (Attisano and Wrana, 2000; Goumans et al., 2002; Lebrin et al., 2004). Protein expression studies have shown that endoglin and ALK1 haploinsufficiency, by mutations that cause loss of function, is the underlying cause of HHT (Pece-Barbara et al., 1999). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hereditary haemorrhagic telangiectasia (HHT), the most common inherited vascular disorder, is predominantly caused by mutations in ENG and ACVRL1, which are part of the transforming growth factor beta (TGF-β) signalling pathway. HHT is characterized by the presence of mucocutaneous telangiectases and arteriovenous malformations in visceral organs, primarily the lungs, brain and liver. The most common symptom in HHT is epistaxis originating from nasal telangiectasia, which can be difficult to prevent and can lead to severe anaemia. The clinical manifestations of HHT are extremely variable, even within family members, and the exact mechanism of how endoglin and ALK1 haploinsufficiency leads to HHT manifestations remains to be identified. The purpose of this study was to detect significantly differentially regulated genes in HHT, and try to elucidate the pathways and regulatory mechanisms occurring in the affected tissue of HHT patients, in order to further characterize this disorder and hypothesize on how telangiectases develop. By microarray technology (Agilent G3 Human GE 8x60), we performed global gene expression profiling of mRNA transcripts from HHT nasal telangiectasial (n=40) and non-telangiectasial (n=40) tissue using a paired design. Comparing HHT telangiectasial and non-telangiectasial tissue, significantly differentially expressed genes were detected using a paired t-test. Gene set analysis was performed using GSA-SNP. In the group of ENG mutation carriers, we detected 67 differentially expressed mRNAs, of which 62 were down regulated in the telangiectasial tissue. Gene set analysis identified the gene ontology (GO) terms vasculogenesis, TGF-β signalling, and Wnt signalling as differentially expressed in HHT1. Altered Wnt signalling might be related to HHT pathogenesis and a greater understanding of this may lead to the discovery of therapeutic targets in HHT. Copyright © 2015. Published by Elsevier Inc.
    Microvascular Research 04/2015; 99. DOI:10.1016/j.mvr.2015.04.002 · 2.13 Impact Factor
  • Source
    • "The expression of endoglin (CD105), an endothelial-specific coreceptor for TGF-b, was reported to increase after anti-VEGF antibody treatment in a pancreatic cancer model (Bockhorn et al., 2003). Endoglin expression is upregulated during tumor angiogenesis and in proliferating EC (Duff et al., 2003), and it functions in facilitating TGF-b/ALK1 signaling (Lebrin et al., 2004; van Meeteren et al., 2012) as well as VEGF signaling (Liu et al., 2014b). Different studies indicate that endoglin is essential for angiogenesis (Bourdeau et al., 1999; Duff et al., 2003). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The concept of antiangiogenic therapy in cancer treatment has led to the approval of different agents, most of them targeting the well known vascular endothelial growth factor pathway. Despite promising results in preclinical studies, the efficacy of antiangiogenic therapy in the clinical setting remains limited. Recently, awareness has emerged on resistance to antiangiogenic therapies. It has become apparent that the intricate complex interplay between tumors and stromal cells, including endothelial cells and associated mural cells, allows for escape mechanisms to arise that counteract the effects of these targeted therapeutics. Here, we review and discuss known and novel mechanisms that contribute to resistance against antiangiogenic therapy and provide an outlook to possible improvements in therapeutic approaches.
    Pharmacological Reviews 03/2015; 67:441-461. · 17.10 Impact Factor
Show more